We are live on ! Find out more
INDP icon

Indaptus Therapeutics
INDP

15 hedge funds and large institutions have $1.06M invested in Indaptus Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,674% more capital inflows, than outflows

Capital inflows: $72.6K | Capital outflows: $1.26K

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

15% more funds holding

Funds holding: 13 → 15 (+2)

0.38% more ownership

Funds ownership: 6.79% → 7.17% (+0.38%)

Holders
15
Holders Change
+2
Holders Change %
+15.38%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$37.1K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$12.4K
3
Renaissance Technologies
Renaissance Technologies
New York
+$11.3K
4
UBS Group
UBS Group
Switzerland
+$7.99K
5
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$3.77K

Top Sellers

Rank Fund Capital Flow
1
Investment House LLC
Investment House LLC
California
-$943
2
Morgan Stanley
Morgan Stanley
New York
-$314

INDP Hedge Fund Activity: Q4 2023 in Review

15 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2023, worth a combined $1.06M — down 33% from $1.57M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new INDP positions and 0 closed out — a net gain of 2 holders — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $37.1K. The largest seller was Investment House LLC, cutting an estimated $943.

  • 15 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2023, up from 13 in Q3 2023.
  • Funds reported $1.06M of Indaptus Therapeutics stock for Q4 2023, down 33% quarter-over-quarter.
  • 2 funds opened new Indaptus Therapeutics positions in Q4 2023 and 0 closed out, a net change of +2 holders.
  • The largest Indaptus Therapeutics buyer in Q4 2023 was Citadel Advisors, an estimated $37.1K added.
  • The largest Indaptus Therapeutics seller in Q4 2023 was Investment House LLC, an estimated $943 sold.

Based on aggregated 13F filings for Q4 2023.